Thetis Pharmaceuticals LLC

Overview

Thetis Pharmaceuticals develops TP-317, a first-in-class oral BLT1 agonist based on Resolvin E1 for inflammatory bowel disease and solid tumor cancers.

Related on NestLens

• Connecticut Innovations · Capital Manager (GP)